Leap Therapeutics (LPTX) & Its Rivals Head to Head Analysis

Leap Therapeutics (NASDAQ:LPTX) is one of 454 public companies in the “Pharmaceutical Preparations” industry, but how does it contrast to its peers? We will compare Leap Therapeutics to similar businesses based on the strength of its dividends, risk, valuation, institutional ownership, earnings, profitability and analyst recommendations.

Profitability

This table compares Leap Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Leap Therapeutics	N/A	-247.44%	-146.51%
Leap Therapeutics Competitors	-2,626.20%	-359.54%	-43.35%

Risk & Volatility

Leap Therapeutics has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500. Comparatively, Leap Therapeutics’ peers have a beta of 10.16, meaning that their average stock price is 916% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Leap Therapeutics and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Leap Therapeutics	1	0	0	0	1.00
Leap Therapeutics Competitors	4831	9975	16021	374	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 118.73%. Given Leap Therapeutics’ peers stronger consensus rating and higher possible upside, analysts clearly believe Leap Therapeutics has less favorable growth aspects than its peers.

Institutional & Insider Ownership

30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 39.3% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 4.3% of Leap Therapeutics shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceutical Preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Leap Therapeutics and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Leap Therapeutics	N/A	-$67.56 million	-1.68
Leap Therapeutics Competitors	$434.13 million	-$68.27 million	-10.33

Leap Therapeutics’ peers have higher revenue, but lower earnings than Leap Therapeutics. Leap Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Leap Therapeutics peers beat Leap Therapeutics on 9 of the 13 factors compared.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.